Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.18B 10.65B 9.77B 9.12B 17.29B 1,159B 17.54B 117B 45.64B 569B 45.71B 44.72B 1,964B P/E 2026 *
-75.7x
P/E 2027 * 53.5x
Enterprise Value 11.65B 10.19B 9.35B 8.73B 16.54B 1,109B 16.78B 112B 43.66B 544B 43.73B 42.77B 1,879B EV / Sales 2026 *
7.79x
EV / Sales 2027 * 5.02x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day+2.67%
1 week+2.79%
Current month-1.65%
1 month+16.61%
3 months-3.44%
6 months-11.07%
Current year-9.31%
1 week 506
Extreme 506
545.87
1 month 460.89
Extreme 460.89
545.87
Current year 416.21
Extreme 416.21
598.79
1 year 284.02
Extreme 284.0228
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 6.6
Extreme 6.6
615
Manager TitleAgeSince
Chief Executive Officer 59 07/09/2023
Director of Finance/CFO 62 10/03/2024
Chief Tech/Sci/R&D Officer 58 20/04/2025
Director TitleAgeSince
Chairman 83 21/07/2016
Director/Board Member 73 30/06/2016
Director/Board Member 68 10/08/2016
Date Insider Type Main position Quantity % Market Cap.
06-16Free

Founder

1,220 0.0053%
06-16
Baker Bros. Advisors LP
FreeCompany 4,880 0.0212%
06-16Free

Director

1,220 0.0053%
Change 5-day change 1-year change 3-year change Capi.($)
+2.67%+2.79%+75.95%+128.61% 12.18B
+0.68%+6.27%+77.60%+133.76% 58.73B
+2.32%+5.89%+76.81%+99.20% 53.92B
+3.86%+8.38%-9.90%-9.62% 24.67B
+4.30%+6.82%+13.60%+428.91% 24.19B
+4.74%+13.47%+46.43%+0.03% 18.8B
-0.29%+8.57%+44.17%-27.58% 17.61B
0.00%+16.74%+171.12%+355.99% 16.25B
+3.50%+4.92%+26.07%+192.26% 14.04B
+6.72%+20.94%+51.67% - 13.9B
Average +2.85%+6.72%+57.35%+144.62% 25.43B
Weighted average by Cap. +2.45%+5.40%+59.87%+136.90%

Financials

2026 *2027 *
Net sales 1.5B 1.31B 1.2B 1.12B 2.12B 142B 2.15B 14.42B 5.61B 69.91B 5.61B 5.49B 241B 2.21B 1.93B 1.77B 1.65B 3.13B 210B 3.18B 21.28B 8.27B 103B 8.28B 8.1B 356B
Net income -201M -176M -161M -151M -285M -19.14B -290M -1.94B -753M -9.4B -755M -738M -32.43B 308M 269M 247M 231M 437M 29.29B 443M 2.97B 1.15B 14.38B 1.16B 1.13B 49.64B
Net Debt -529M -463M -425M -397M -751M -50.38B -763M -5.1B -1.98B -24.74B -1.99B -1.94B -85.38B -1.09B -957M -879M -820M -1.55B -104B -1.58B -10.56B -4.1B -51.18B -4.11B -4.02B -177B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
02/07/26 US$528.10 +2.67% 221,894
01/07/26 US$514.39 -4.20% 303,751
30/06/26 US$536.95 +1.83% 393,459
29/06/26 US$527.28 +2.85% 446,960
26/06/26 US$512.65 -0.22% 2,500,271
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
528.10USD
Average target price
678.71USD
Spread / Average Target
+28.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock